Compare TLF & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLF | NCEL |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 4 |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 17.2M |
| IPO Year | 2006 | N/A |
| Metric | TLF | NCEL |
|---|---|---|
| Price | $2.33 | $3.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 39.4K | 30.5K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 32.05% | N/A |
| EPS Growth | ★ 1122.22 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $76,324,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $78.33 | ★ N/A |
| Revenue Growth | ★ 2.60 | N/A |
| 52 Week Low | $2.20 | $1.83 |
| 52 Week High | $3.78 | $5.12 |
| Indicator | TLF | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 50.65 |
| Support Level | $2.25 | $2.95 |
| Resistance Level | $2.45 | $3.62 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 32.35 | 77.98 |
Tandy Leather Factory Inc is a specialty retailers of leather and leathercraft-related items. Its primary line of business is the sale of leather, leather crafts, and related supplies. Its broad line of leather and related products includes leather, leatherworking tools, leather dyes and finishes, and do-it-yourself kits. Its products include Leather, tools, Hardware, Supplies, Kits, Books and Patterns, and Gift cards. The company sells its products primarily through company-owned stores and through orders generated from its global websites, and through direct account representatives in its commercial division. Geographically the company operates within the United States, and Canada. it generates the highest revenue from the United States.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.